Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Biosimilars: Global Markets" has been added to ResearchAndMarkets.com's offering.
The global biosimilars market is on an impressive growth trajectory, with the market valued at $23.8 billion in 2023 and forecasted to expand at a compound annual growth rate (CAGR) of 19.4% to reach $69.2 billion by the end of 2029.
The surge in market value is primarily driven by patent expirations of major biologics and the cost-effectiveness of biosimilars, which offer significant healthcare savings. However, the expansion is tempered by challenges related to intellectual property, legal issues, and manufacturing complexities.
Monoclonal antibodies captured the largest share in 2023, expected to grow at a robust CAGR of 19.8% through the forecast period. Among therapeutic applications, the autoimmune and inflammatory diseases segment is poised to grow fastest, at a 20.1% CAGR, while the cancer and related disorders segment dominated in 2023, holding a 34.2% market share and projected to value at $24 billion by 2029.
In regional terms, Europe leads with a 45.8% market share in 2023, courtesy of early adoption, supportive regulations, and favorable government policies. North America, Asia-Pacific, and the Rest of the World are other key markets contributing to the biosimilars industry's dynamics.
This report offers a comprehensive analysis of the biosimilars market, including in-depth insights into current and future potentials, market drivers, and challenges. It encompasses detailed segmentation based on product type, therapeutic applications, and geographical regions. Key segments include monoclonal antibodies, recombinant growth factors, and therapeutic applications like cancer, autoimmune diseases, diabetes, and more.
The analysis integrates critical data, featuring 142 data tables and 74 additional tables, with historic revenue data from 2021 and 2022, estimates for 2023, and projections through 2029, supporting strategic market decisions. It provides an overview of the industry's structure, emerging trends, and innovations in biosimilars.
Key players in the market like Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are profiled, with insights into their business strategies, financials, and product developments. The competitive landscape, market shares, strategic alliances, and merger and acquisition activities are extensively analyzed.
The report also delves into sustainability trends and ESG developments, emphasizing consumer attitudes and practices of leading companies. It features insights from Porter's Five Forces model and includes global supply chain and PESTLE analyses.
As the biosimilars market continues to evolve, this report serves as an essential resource for stakeholders seeking to navigate the complexities of this dynamic industry.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 219 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value (USD) in 2024 | $28.5 Billion |
| Forecasted Market Value (USD) by 2029 | $69.2 Billion |
| Compound Annual Growth Rate | 19.4% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Market Overview
- Terminology of Biosimilars
- Key Terms in Biosimilars
- WHO Guidelines on Evaluation of Biosimilars
- Pharmacovigilance/Post-Approval Monitoring
- Biosimilars Vs. Biobetters
- Popular Types of Biosimilars
- Recombinant Hormones
- Recombinant Growth Factors
- Monoclonal Antibodies (mAbs)
- Fusion Proteins
- Interferons
- Low Molecular Weight Heparins (LMWHs)
Chapter 3 Market Dynamics
- Market Drivers
- Patent Expirations of Major Biologics
- Cost-effectiveness and Healthcare Savings
- Market Restraints
- Intellectual Property and Legal Issues
- Manufacturing and Supply Chain Complexities
- Market Opportunities
- Increasing Access, Adoption and Awareness
- Emerging Markets
Chapter 4 Emerging Technologies
- Advanced Analytical Techniques
- Single-use Bioreactors
- Cell Line Engineering and Expression Systems
Chapter 5 Market Segmentation Analysis
- Global Biosimilars Market, by Product Type
- Monoclonal Antibodies
- Recombinant Growth Factors
- Recombinant Hormones
- Fusion Protein
- Others
- Global Biosimilars Market, by Therapeutic Application
- Cancer and Related Disorders
- Autoimmune and Inflammatory Diseases
- Diabetes
- Anemia
- Growth Hormone Deficiency
- Other Diseases
- Global Biosimilars Market, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Chapter 6 Competitive Landscape and Patent Analysis
- Key Market Leaders
- Emerging Players
- Strategic Analysis
- Challenges and Future Trends
- Patent Analysis
- Patent Regulations in Favor of Branded Biologics
- Market Exclusivity
Chapter 7 Regulatory Aspects
- Biosimilar Regulations in Europe
- Biosimilar Regulations in the U.S.
- Principle of Exclusivity
- Biosimilar Regulations in China
Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective
- Introduction to ESG
- ESG Practices in the Biosimilars Industry
- Concluding Remarks
Companies Featured
- Accord Biopharma Inc.
- Alvotech
- Amgen Inc.
- Amneal Pharmaceuticals LLC
- Biocon Biologics Ltd.
- Biogen
- Celltrion Inc.
- Coherus Biosciences
- Fresenius Kabi AG
- Lilly
- Pfizer Inc.
- Samsung Bioepis
- Sandoz Group AG
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc
For more information about this report visit https://www.researchandmarkets.com/r/unob4a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
